Data from the remaining two groups are now available, confirming the ability of ABNCoV2 to boost neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-21
Plan to initiate Phase 3 during the first half of 2022
Sunday, February 27, 2022
Bavarian Nordic: Positive Phase 2 Results for COVID-19 Vaccine Candidate Ahead of Phase 3 Trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.